The Europe Hospital-Acquired Infection Diagnostics Market is expected to witness market growth of 7.1% CAGR during the forecast period (2022-2028).
In identifying the likely source of infection and exposing evidence of organ dysfunction, laboratory testing supports the clinical and history examination. Lactic acid, prothrombin time, liver transaminases, blood urea nitrogen (BUN), and serum creatinine levels can all be used to back up clinical hypoperfusion findings. Low or high white cell counts, raised bands, hypoglycemia, thrombocytopenia, hyperglycemia, and impaired mixed venous blood saturation are all relevant test results. Collecting samples for cultures prior to starting antibiotics is critical for determining the pathogen and antimicrobial susceptibility pattern immediately on. The pathogen's vulnerability as well as the antibiotic's vulnerability assist narrow the field from broad-spectrum antibiotics to pathogen-specific medicines. Investigations that do not change clinical decision-making or the course of treatment are generally not advised. C-reactive protein (CRP) and procalcitonin tests are deemed auxiliary and not advised if the pre-test probability of a HAI like ventilator-associated pneumonia/VAP is high. For instance, recent IDSA guidelines advocate tracheal aspirates for patients with HAP/VAP because it have been demonstrated to have a non-inferior yield when matched to invasive sampling methods like bronchoscopy or quantitative tracheal lavage.
The Europe region is being suffered from hospital-acquired infections and those infections are fatal in the nature, which increases the importance of hospital-acquired infection diagnostics system. Between 2016 and 2017, 310,755 patients from 1,209 acute care hospitals in 28 countries participated in point prevalence surveys of healthcare-associated infections (HAI) and antimicrobial usage in the European Union and European Economic Area (EU/EEA). After nationwide validation, it was estimated that 6.5 percent of patients in acute care hospitals had at least one HAI. In acute care hospitals, 98,166 patients had a HAI on any given day, and 3.8 million patients had a HAI each year.
A European investigation of HCAIs linked to respiratory infection reported an incidence rate of 7.59 percent in the United Kingdom and Ireland. Pneumonia accounted for 15.7 percent of the HCAIs, whereas lower respiratory tract infections apart from pneumonia accounted for 7%. Artificial ventilation was used by approximately 21% of patients in both groups, which was much greater than the remainder of the HCAI patients. For both pneumonia and LRTIOP, the main invading bacterium was MRSA. LRTIOP patients had more C.
The Germany market dominated the Europe Hospital-Acquired Infection Diagnostics Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $358.1 million by 2028. The UK market is anticipated to grow at a CAGR of 6.2% during (2022 - 2028). Additionally, The France market is expected to showcase a CAGR of 7.9% during (2022 - 2028).
Based on Product, the market is segmented into Reagents & Consumables and Instrument. Based on Infection Type, the market is segmented into Urinary Tract Infections (UTI), Hospital Acquired Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infections, and Others. Based on Application, the market is segmented into Drug-Resistance Testing and Disease Testing. Based on Test Type, the market is segmented into Molecular Diagnostics, Immunoassay, and Urinalysis. Based on End User, the market is segmented into Hospital, Standalone Laboratories, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG (Bayer Schering Pharma AG), Danaher Corporation, Becton, Dickinson and Company, Hologic, Inc., Ecolab, Inc., Pfizer, Inc., Steris PLC, Johnson & Johnson, Abbott Laboratories, and Merck Group.
In identifying the likely source of infection and exposing evidence of organ dysfunction, laboratory testing supports the clinical and history examination. Lactic acid, prothrombin time, liver transaminases, blood urea nitrogen (BUN), and serum creatinine levels can all be used to back up clinical hypoperfusion findings. Low or high white cell counts, raised bands, hypoglycemia, thrombocytopenia, hyperglycemia, and impaired mixed venous blood saturation are all relevant test results. Collecting samples for cultures prior to starting antibiotics is critical for determining the pathogen and antimicrobial susceptibility pattern immediately on. The pathogen's vulnerability as well as the antibiotic's vulnerability assist narrow the field from broad-spectrum antibiotics to pathogen-specific medicines. Investigations that do not change clinical decision-making or the course of treatment are generally not advised. C-reactive protein (CRP) and procalcitonin tests are deemed auxiliary and not advised if the pre-test probability of a HAI like ventilator-associated pneumonia/VAP is high. For instance, recent IDSA guidelines advocate tracheal aspirates for patients with HAP/VAP because it have been demonstrated to have a non-inferior yield when matched to invasive sampling methods like bronchoscopy or quantitative tracheal lavage.
The Europe region is being suffered from hospital-acquired infections and those infections are fatal in the nature, which increases the importance of hospital-acquired infection diagnostics system. Between 2016 and 2017, 310,755 patients from 1,209 acute care hospitals in 28 countries participated in point prevalence surveys of healthcare-associated infections (HAI) and antimicrobial usage in the European Union and European Economic Area (EU/EEA). After nationwide validation, it was estimated that 6.5 percent of patients in acute care hospitals had at least one HAI. In acute care hospitals, 98,166 patients had a HAI on any given day, and 3.8 million patients had a HAI each year.
A European investigation of HCAIs linked to respiratory infection reported an incidence rate of 7.59 percent in the United Kingdom and Ireland. Pneumonia accounted for 15.7 percent of the HCAIs, whereas lower respiratory tract infections apart from pneumonia accounted for 7%. Artificial ventilation was used by approximately 21% of patients in both groups, which was much greater than the remainder of the HCAI patients. For both pneumonia and LRTIOP, the main invading bacterium was MRSA. LRTIOP patients had more C.
The Germany market dominated the Europe Hospital-Acquired Infection Diagnostics Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $358.1 million by 2028. The UK market is anticipated to grow at a CAGR of 6.2% during (2022 - 2028). Additionally, The France market is expected to showcase a CAGR of 7.9% during (2022 - 2028).
Based on Product, the market is segmented into Reagents & Consumables and Instrument. Based on Infection Type, the market is segmented into Urinary Tract Infections (UTI), Hospital Acquired Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infections, and Others. Based on Application, the market is segmented into Drug-Resistance Testing and Disease Testing. Based on Test Type, the market is segmented into Molecular Diagnostics, Immunoassay, and Urinalysis. Based on End User, the market is segmented into Hospital, Standalone Laboratories, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG (Bayer Schering Pharma AG), Danaher Corporation, Becton, Dickinson and Company, Hologic, Inc., Ecolab, Inc., Pfizer, Inc., Steris PLC, Johnson & Johnson, Abbott Laboratories, and Merck Group.
Scope of the Study
Market Segments Covered in the Report:
By Product
- Reagents & Consumables
- Instrument
By Infection Type
- Urinary Tract Infections (UTI)
- Hospital Acquired Pneumonia
- Bloodstream Infections
- Surgical Site Infections
- Gastrointestinal Infections
- Others
By Application
- Drug-Resistance Testing
- Disease Testing
By Test Type
- Molecular Diagnostics
- Immunoassay
- Urinalysis
By End User
- Hospital
- Standalone Laboratories
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Bayer AG (Bayer Schering Pharma AG)
- Danaher Corporation
- Becton, Dickinson and Company
- Hologic, Inc.
- Ecolab, Inc.
- Pfizer, Inc.
- Steris PLC
- Johnson & Johnson
- Abbott Laboratories
- Merck Group
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Europe Hospital-Acquired Infection Diagnostics Market by Product
Chapter 5. Europe Hospital-Acquired Infection Diagnostics Market by Infection Type
Chapter 6. Europe Hospital-Acquired Infection Diagnostics Market by Application
Chapter 7. Europe Hospital-Acquired Infection Diagnostics Market by Test Type
Chapter 8. Europe Hospital-Acquired Infection Diagnostics Market by End User
Chapter 9. Europe Hospital-Acquired Infection Diagnostics Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- Bayer AG (Bayer Schering Pharma AG)
- Danaher Corporation
- Becton, Dickinson and Company
- Hologic, Inc.
- Ecolab, Inc.
- Pfizer, Inc.
- Steris PLC
- Johnson & Johnson
- Abbott Laboratories
- Merck Group
Methodology
LOADING...
